GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Synektik SA (STU:A2P) » Definitions » Cash And Cash Equivalents

Synektik (STU:A2P) Cash And Cash Equivalents : €44.5 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Synektik Cash And Cash Equivalents?

Synektik's quarterly cash and cash equivalents increased from Jun. 2024 (€18.21 Mil) to Sep. 2024 (€20.04 Mil) and increased from Sep. 2024 (€20.04 Mil) to Dec. 2024 (€44.55 Mil).

Synektik's annual cash and cash equivalents declined from Sep. 2021 (€4.34 Mil) to Sep. 2022 (€2.30 Mil) but then increased from Sep. 2022 (€2.30 Mil) to Sep. 2023 (€14.89 Mil).


Synektik Cash And Cash Equivalents Historical Data

The historical data trend for Synektik's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synektik Cash And Cash Equivalents Chart

Synektik Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.03 2.58 4.34 2.30 14.89

Synektik Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.31 17.02 18.21 20.04 44.55

Synektik Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Synektik  (STU:A2P) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Synektik Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Synektik's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Synektik Business Description

Traded in Other Exchanges
Address
Aleja Wincentego Witosa 31, Warsaw, POL, 00-710
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.

Synektik Headlines

No Headlines